Today
+2.50%
5 Days
-0.63%
1 Month
-14.25%
6 Months
+217.19%
Year to Date
+217.19%
1 Year
+74.61%
P3 Health Partners Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 153 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.00.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Media Coverage
TradingKey - P3 Health Partners is at $12.38 after pulling back from $18.52 post-earnings high. Ascending trendline from $5.91 intact. Q1 net income +$3M vs -$44M prior year. EBITDA $26M. Target $14.16.

TradingKey - P3 Health Partners Q1 2026: EPS +$0.32 vs -$4.85 estimate. Medical margin jumped from $49 to $231 per member. 2026 EBITDA guidance raised to $20–$60M. Lake Street target raised to $14. PIII at $10.



Related Instruments
Popular Instruments